Cite
HARVARD Citation
Tsujikawa, L. et al. (2018). Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells. Atherosclerosis. pp. 104-. [Online].